SKLB325 is a Jumonji domain-containing 6 ( JMJD6 ) inhibitor with a binding affinity ( K D ) value of 0.755 μM, and the IC 50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis. SK In Vitro:SKLB325 suppresses ovarian cancer growth through inhibition of proliferation and induction of apoptosis and cell death, and inhibiting angiogenesis may play a significant role in inhibiting tumor growth. SKLB325 (0.25-16 μM; for 24-72 h) has signific In Vivo:SKLB325 (10mg/kg) has antitumor activities in an intraperitoneal xenograft model. SKLB325 significantly prolongs the survival of tumor-bearing mice without obvious side effects. SKLB325 treatment protocols were effective in suppressing SKOV3, ES2, CP70, Biological Activity:SKLB325 is a Jumonji domain-containing 6 ( JMJD6 ) inhibitor with a binding affinity ( K D ) value of 0.755u2009μM, and the IC 50 value of 0.7797u2009μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
SKLB325
CAS number：unknown molecular formula：C12H12N4O2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | unknown | molecular formula | C12H12N4O2 |
| molecular weight | 244.25 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
